Reviva to Participate in the Spartan Capital Securities Second Annual Investor Conference

Core Insights - Reviva Pharmaceuticals Holdings, Inc. is a late-stage pharmaceutical company focused on developing therapies for unmet medical needs in central nervous system (CNS), inflammatory, and cardiometabolic diseases [1][4] - The company will be represented by its Founder, President, and CEO, Laxminarayan Bhat, at the Spartan Capital Securities Second Annual Investor Conference on November 3, 2025, in New York City [1] Company Overview - Reviva's current pipeline includes two drug candidates: brilaroxazine (RP5063) and RP1208, both of which are new chemical entities discovered in-house [4] - The company has been granted composition of matter patents for both drug candidates in the United States, Europe, and several other countries [4] Conference Details - The Spartan Capital Securities conference will feature over 60 selected companies across various sectors, including technology, healthcare, and consumer [2] - More than 500 institutional and high-net-worth investors are expected to attend, providing opportunities for dialogue between growth companies and the investment community [2]